Reslizumab
Top View
- International Nonproprietary Names (Inn) for Biological and Biotechnological Substances
- CDER List of Licensed Biological Products With
- (INN) for Biological and Biotechnological Substances
- Cai HH. Therapeutic Monoclonal Antibodies Approved by FDA In
- Cinqaero, INN-Reslizumab
- WO 2018/067987 Al 12 April 2018 (12.04.2018) W !P O PCT
- Clinical Rx Forum Volume 5 Issue 2
- (12) United States Patent (10) Patent No.: US 9,446,134 B2 Maggio (45) Date of Patent: *Sep
- Anti-IL5 Therapies for Asthma (Review)
- International Nonproprietary Names (INN) for Biological and Biotechnological Substances
- Aaai-Aid1026.Pdf
- Diagnosis and Management of Rhinosinusitis: a Practice Parameter Update
- Emerging Therapeutic Options for the Treatment of Patients with Symptomatic Asthma R
- Roche Reviewing Next Steps for Lebrikizumab After Mixed Phase III Data
- Immunology [ Edition ]
- Monoclonal Antibodies in Asthma
- CINQAIR (Reslizumab) Injection, for Intravenous Use • Reduction in Corticosteroid Dosage: Do Not Discontinue Systemic Or Initial U.S
- CINQAIR (Reslizumab)